Navigation Links
Syndexa Pharmaceuticals Corporation and ChemDiv, Inc. Announce Discovery Collaboration

SAN DIEGO and CAMBRIDGE, Mass., April 28 /PRNewswire/ -- ChemDiv, Inc., a global CRO for drug discovery & development, and Syndexa Pharmaceuticals Corporation, a biopharmaceutical company developing first-in-class drugs for the treatment of metabolic diseases, have announced today the signing of a collaborative discovery research agreement. Under the terms of the agreement, ChemDiv will discover small molecule ligands for biotargets nominated by Syndexa. Financial terms of the collaboration were not disclosed.

"We are very excited to deploy our discovery resources in this collaboration with Syndexa," said Dr. Ilya Okun, VP of Biology & CTO at ChemDiv, Inc. "ChemDiv's flexible service capabilities emphasize delivery of rapid, high-value results for our partners' drug discovery programs. We are able to realize that goal through the creative integration of the chemistry and biology components of our Discovery outSource(TM) platform."

"We are extremely pleased to be working with ChemDiv, a drug discovery partner with a strong track record. The collaboration will provide us with access to high quality screening capabilities and compound library resources. We anticipate that this project will accomplish our goal of discovering promising drug leads to enhance our R&D pipeline," said Teo Uysal, President and CEO, Syndexa Pharmaceuticals.

About ChemDiv, Inc.:

ChemDiv, Inc. (Chemical Diversity) is a global CRO delivering discovery opportunities and services for life science partners. ChemDiv is merging industrial and academic efforts to bring new approaches to the treatment of life-threatening diseases. Drawing on a long heritage in small-molecule chemistry research, a dedicated and personal approach to collaborative research and development as well as world class personnel and physical resources, ChemDiv provides partners with access to Discovery outSource(TM) a full service drug discovery offering encompassing synthetic chemistry; medicinal chemistry, diverse & focused screening libraries, global logistics and wide range of biology services for pre-clinical discovery & development projects.

About Syndexa Pharmaceuticals Corporation:

Syndexa is engaged in the discovery and development of a new generation of small-molecule drugs that target the biological interface between inflammatory and metabolic pathways, and provide a novel mechanism for the treatment and prevention of metabolic diseases including obesity, type 2 diabetes and atherosclerosis. Syndexa's current programs include the development of inhibitors of obesity-induced Endoplasmic Reticulum (ER) stress and c-jun N-terminal kinase (JNK). Founded by leading scientists from Harvard and University of California, San Diego, the company is executing on its business strategy to rapidly build and commercialize a portfolio of breakthrough products. The company is headquartered in Cambridge, MA. For additional information, please visit

SOURCE ChemDiv, Inc.; Syndexa Pharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Aida Pharmaceuticals, Inc. Announces Update on Progress of Rh-Apo2L Testing
2. Schering-Plough/MERCK Pharmaceuticals Receives Not-Approvable Letter from FDA for Loratadine/Montelukast
3. Keryx Biopharmaceuticals Receives Nasdaq Notification
4. Amylin Pharmaceuticals to Present at Morgan Stanley Global Healthcare Unplugged Conference
5. Idenix Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
6. Aida Pharmaceuticals, Inc. Announces Completion of Research Institute Acquisition
7. Anadys Pharmaceuticals to Report First Quarter 2008 Financial Results
8. New Fragment-based Drug Discovery Platform Announced Between IOTA Pharmaceuticals Ltd, Cambridge (UK), and Beactica AB, Uppsala (Sweden)
9. MacroChem Acquires Virium Pharmaceuticals
10. GlaxoSmithKline to Acquire Sirtris Pharmaceuticals, a World Leader in Sirtuin Research and Development
11. Rib-X Pharmaceuticals to Present at Cambridge Healthtech Institutes 2nd Annual Challenge of Antibacterial Development Conference
Post Your Comments:
(Date:11/25/2015)... LOS ANGELES and HOLLISTON, Mass. ... Regenerative Technology, Inc. (Nasdaq: HART ), a biotechnology ... announced that CEO Jim McGorry will present ... Tuesday, December 1, 2015 at 2:30 p.m. PT. The ... (link below) for 30 days. Management will also be ...
(Date:11/25/2015)... ... November 25, 2015 , ... A long-standing ... Aerospace Professionals (OPBAP) has been formalized with the signing of a Memorandum of ... with OPBAP leaders Capt. Karl Minter and Capt. Albert Glenn Tuesday, November 24, ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... ... company uBiome, were featured on AngelList early in their initial angel funding process. ... AngelList syndicate for individuals looking to make early stage investments in the microbiome ...
(Date:11/24/2015)... , Nov. 24, 2015 Cepheid (NASDAQ: ... speaking at the following conference, and invited investors to ... NY      Tuesday, December 1, 2015 at 11.00 ... NY      Tuesday, December 1, 2015 at 11.00 ... Conference, New York, NY      Tuesday, ...
Breaking Biology Technology:
(Date:11/17/2015)... 17, 2015 Paris from ... --> Paris from 17 th until ... biometrics innovation leader, has invented the first combined scanner in ... same scanning surface. Until now two different scanners were required: ... can capture both on the same surface. This innovation ...
(Date:11/17/2015)... 2015  Vigilant Solutions announces today that Mr. ... Directors. --> --> ... the partnership at TPG Capital, one of the largest ... Billion in revenue.  He founded and led TPG,s Operating ... companies, from 1997 to 2013.  In his first role, ...
(Date:11/16/2015)... JOSE, Calif. , Nov 16, 2015 /PRNewswire/ ... developer of human interface solutions, today announced expansion ... Synaptics TouchView ™ touch controller and display ... architectural revolution of smartphones. These new TDDI products ... include TD4100 (HD resolution), TD4302 (WQHD resolution), and ...
Breaking Biology News(10 mins):